Navigation Links
Combo Therapy may Be Highly Beneficial in Asthma Control

A new study has found that combination asthma therapy, SYMBICORT leads to significant improvements in health-related quality of life (HRQL) and greater patient-reported satisfaction with asthma treatment, versus its monocomponents (budesonide or formoterol or placebo).

SYMBICORT is a recently approved, combination therapy indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older. SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.

SYMBICORT is a combination of two proven asthma medications budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta agonist (LABA).

As part of the 12-week, randomised, double-blind, placebo-controlled, multicenter study, researchers measured HRQL in 553 patients with moderate-to-severe persistent asthma treated with one of five SYMBICORT therapies.

The patients were subjected to two inhalations with SYMBICORT in one pressurised meter-dose inhaler (pMDI) 160/4.5 micrograms (mcg); budesonide pMDI 160 mcg; formoterol via dry-powder inhaler (DPI) 4.5 mcg; budesonide pMDI 160 mcg + formoterol DPI 4.5 mcg in separate inhalers; or placebo, each bid.

HRQL was assessed using the standardised Asthma Quality of Life Questionnaire [AQLQ(S)], a validated survey that measures how asthma affects a person's daily activities, emotional functioning, and symptoms and using patient and physician global assessments.

The study also measured satisfaction to treatment in 390 patients with mild-to-moderate asthma previously treated with inhaled corticosteroids. Patients were randomised to receive treatment with two inhalations with SYMBICORT 80/4.5 mcg, budesonide pMDI 80 mcg, formoterol DPI 4.5 mcg, or placebo, each bid.

Patient satisfaction was assessed using three indices of the Patient Satisfaction with Asthma Medication (PSAM) questi onnaire, which measures relief of symptoms, perception of medication, and comparison with other medications based on a score of 1 (lowest) to 100 (highest).

Researchers found that SYMBICORT led to statistically significant and clinically meaningful improvements in AQLQ(S) scores versus formoterol DPI or placebo. SYMBICORT also significantly improved AQLQ(S) scores, compared with budesonide pMDI on all measures except for emotional function.

Also, SYMBICORT resulted in significantly high satisfaction scores.

The findings of the study were presented at the American Thoracic Society (ATS) 2007 International Conference held in San Francisco.


'"/>




Related medicine news :

1. Drug Combo Works Better for children with ADHD, Tics
2. Scanning Combo Helps Detect Lung Cancer
3. Relief From Asthma With New Combo Therapy
4. Calcium-Vitamin D Combo For Reduced Fracture Risk
5. Drug Combo Improves Performance Of Multiple Sclerosis Drug
6. Alcohol-illusion: Alcohol and Energy Drinks Combo, Maintains Sobriety?
7. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
8. The Combo Treatment Is Effective to Treat Type 1 Diabetes in Mice
9. Doomed Duo: Obesity and Type 2 Diabetes Combo, Can Nip Life in the Bud
10. Arimidex-Herceptin Combo Therapy For Breast Cancer-Clinical Trial Findings
11. Fuzeon and MK-0518 Combo Holds Promise For HIV
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
(Date:6/24/2016)... FL (PRWEB) , ... June 24, 2016 , ... Finally, ... common after venous procedures, dermaka cream can be incorporated into the post-surgical treatment plans ... minor surgical procedures. , dermaka cream is very effective for bruising and causes ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology: